TD2 and Navigating Cancer team up to bring patient-reported outcomes to clinical trials
Posted: 20 April 2015 |
TD2 and Navigating Cancer are teaming up to improve patient engagement in trials and bring patient-reported outcomes to the clinical trials process…
TD2, an oncology development organisation, and Navigating Cancer, the leading web-based patient care and engagement solution for oncology clinics, have entered in to a partnership to improve the engagement of patients in clinical trials and bring patient-reported outcomes to the clinical trials process.
Patients participating in TD2-managed clinical trials will be able to give feedback through a simple-to-use mobile application
The integration with Navigating Cancer’s mobile care management solution will allow patients participating in TD2-managed clinical trials to record adherence and report how they are feeling in real time through a simple-to-use mobile application. This information will be provided to TD2’s participating oncology trial sites to enhance the care of patients enrolled in clinical studies. This access to patient-reported experiences on emerging therapies will provide biotechnology and pharmaceutical companies with new insights that could be used to improve trial designs, develop unique clinical trial endpoints and add value in reimbursement decisions.
TD2 will use real-time patient reported data for more efficient patient-focused clinical trial designs
“Real-time patient reported data using Navigating Cancer’s mobile solution is an important component of the TD2 clinical trial process,” said TD2 CEO Stephen Gately, Ph.D. “ This data will be used to support more efficient patient-focused clinical trial designs, and to potentially identify regulatory opportunities for new medicines that improve patient symptoms and functional abilities.”
“As a company dedicated to improving health outcomes through patient engagement, we believe that providing patients in clinical trials with a convenient, mobile means of reporting their own experiences on an investigative therapy in real time will be a game-changer for patient-centered drug development.” said Gena Cook, CEO of Navigating Cancer. “We are excited to partner with TD2 to ensure that patient’s experiences are reflected in health outcomes.”
For more information about Navigating Cancer, please visit navigatingcancer.com.
For more about TD2, please visit td2inc.com.
